Navigation Links
Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
Date:9/21/2009

u-like symptoms associated with Zometa administration, make this an exciting potential treatment option for advanced cancer patients."

Bone metastases, the spread of tumors to the bone, are a serious concern for many advanced cancer patients. When cancer spreads to the bone, the growing cancer cells weaken and destroy the bone around the tumor. This damage can result in a number of serious bone complications, collectively called skeletal related events.

Denosumab also delayed the median time to first on-study SRE or hypercalcemia of malignancy (HCM) compared to Zometa (hazard ratio 0.83, 95 percent CI: 0.71, 0.97; p=0.02). The median time to first on-study SRE or HCM was 19.0 months for denosumab and 14.4 months for Zometa.

Bone destruction is a major cause of pain in approximately 70 percent of patients with metastatic disease. (1) In an exploratory analysis, patients on the denosumab arm reported worsening of pain later than those on the Zometa arm (57 days versus 36 days, respectively).

Adverse events rates (96 percent denosumab, 96 percent Zometa) and serious adverse events (63 percent denosumab, 66 percent Zometa) were similar between groups and were consistent with what has previously been reported for these two agents. Rates of osteonecrosis of the jaw (ONJ) were balanced and infrequent in both treatment groups (10 patients receiving denosumab as compared with 11 patients receiving Zometa). Infectious adverse events were balanced between the two treatment arms, as was overall survival (hazard ratio 0.95, 95 percent CI: 0.83-1.08; p=0.43) and the time to cancer progression (hazard ratio 1.00, 95 percent CI: 0.89, 1.12; p=1.0).

Detailed data from a second Phase 3, head-to-head trial evaluating denosumab versus Zometa will be presented Tuesday, Sept. 22, 2009 at 14:15 - 14:30 Central European Summer Time (CEST) in the Presidential Session of ECCO-ESMO (Abstract #2L
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... report is available in its catalogue: ... and Technologies for Advanced Drug Delivery ... Administration http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) today announced ... of 2013 on Monday, February 3, 2014. A press release ... of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... operating highlights and financial results for the fourth quarter and ...
(Date:1/14/2014)... 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System ... accompanying instrumentation to place and insert the screw accurately ... tissue (e.g. ligament) repair or reconstruction as it holds ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) The ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... MiMedx Group, Inc.  (OTCBB: MDXG), an integrated developer, manufacturer ... processed from human amniotic membrane, announced today its results ... 30, 2011. The Company recorded record revenue ... over second quarter of 2011 revenue of $1,929,000 and ...
... Oct. 26, 2011 Reportlinker.com ... research report is available in ... Early Stage Drug Safety Strategies ... towards achieving clinical success ...
Cached Medicine Technology:MiMedx Group Announces Third Quarter 2011 Results 2MiMedx Group Announces Third Quarter 2011 Results 3MiMedx Group Announces Third Quarter 2011 Results 4MiMedx Group Announces Third Quarter 2011 Results 5MiMedx Group Announces Third Quarter 2011 Results 6MiMedx Group Announces Third Quarter 2011 Results 7MiMedx Group Announces Third Quarter 2011 Results 8MiMedx Group Announces Third Quarter 2011 Results 9MiMedx Group Announces Third Quarter 2011 Results 10Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 2Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 3Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 4Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 5Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 6Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 7Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 8
(Date:4/20/2014)... cell in the lining of the bladder is responsible ... researchers at the Stanford University School of Medicine. , ... pinpoint the normal cell type that can give rise ... show that most bladder cancers and their associated precancerous ... many human bladder cancers recur after therapy. , "We,ve ...
(Date:4/18/2014)... Hopkins University School of Medicine researchers have been awarded ... diabetes, Novo Nordisk announced this month. Of the 110 ... Obesity Biologics Science Forum Program, only four projects were ... researchers. They are Jonathan Powell, M.D., Ph.D.; G. William ... Jonathan Powell, a professor of oncology, will use his ...
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... pain relief targets that could be used to ... King,s College London made the discovery when researching ... of the body. , Dr Marzia Malcangio said: ... pain generation and our findings could help chemotherapy ... One potential side effect of some chemotherapy drugs ...
(Date:4/17/2014)... 2014) Two recent papers by a University ... may help scientists develop treatments or vaccines for ... encephalitis and other disease-causing flaviviruses. , Jeffrey S. ... genetics at the School of Medicine and an ... Institute, and colleagues recently published articles in the ...
Breaking Medicine News(10 mins):Health News:Stanford scientists identify source of most cases of invasive bladder cancer 2Health News:Stanford scientists identify source of most cases of invasive bladder cancer 3Health News:Stanford scientists identify source of most cases of invasive bladder cancer 4Health News:Stanford scientists identify source of most cases of invasive bladder cancer 5Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2
... Expectant mothers who have lower intake of folic acid ... higher chance of having babies with low birth weight ... Tyne, UK, had found that increased levels of folic ... of newborns, and vice versa. ,Researchers have examined ...
... combing of wet hair may be far more effective ... ,Researchers have used single blind randomized controlled trial for ... insecticide treatments against head lice in United Kingdom. , ... effective than current over the counter chemical treatments for ...
... to mothers who have low levels of foliate// in their ... ,Folate is essential for fetal growth and gene expression. ... and maintain new cells. It is a B vitamin and ... ,Women are usually prescribed folic acid supplements, a synthetic ...
... of $7 million for upgrading a medical college in ... Sardar Vallavbhai Patel Postgraduate Institute of Paediatrics (in Cuttack) ... dispensation of healthcare to a wider population," said a ... the project were signed and exchanged here Thursday by ...
... memories of unpleasant experiences with unhealthy foods could be ... Loftus of the University of California, Irvine, and her ... eating strawberry ice cream as a child. , ... about food. The volunteers subsequently received feedback on their ...
... Researchers have developed a portable la-chip called Genotyper that ... within hours and help the doctors to treat patients ... the Genotyper is on its way to become fully ... all around the world to track the various flu ...
Cached Medicine News:Health News:Study Links Folic Acid With Increased Birth Weight 2Health News:Combing Hair More Effective Than OTC Medicine For Head Lice 2Health News:Vitamin Supplements During Pregnancy to Boost Fetal Development 2Health News:Unpleasant Memory of Food could Be Used to Treat Obesity 2Health News:New Tools To Identify Flu Strains 2
Rapid Infectious Mononucleosis Heterophile Antibody (IgM) Test...
... The Accutest Infectious Mononucleosis Whole Blood ... used for the detection of IgM ... in human whole blood. This test ... in the diagnosis of IM in ...
... ZstatFlu is the first available point-of-care ... diagnose all strains of influenza A and ... for influenza neuraminidase, an enzyme that assists ... the virus from infected cells. The ZstatFlu ...
The NOW® Flu B test is the most frequently adopted rapid flu test on the market today. Testing could not be easier and the results are available in 15 minutes. Now you can focus on the results an...
Medicine Products: